Listed

Vericel Corp: Form 10-Q for the period ended Sep 30, 2015

Filed with the SEC on Nov 13, 2015 and accepted by EDGAR at Nov 13, 2015, 14:51 ET.

Share

Management's discussion and analysis

As filed, 33,324 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Overview

Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. We market two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. We are also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Acquisition of Sanofi’s CTRM Business

On May 30, 2014, we completed the acquisition of the Cell Therapy and Regenerative Medicine (CTRM) business of Sanofi, a French société anonyme (Sanofi), certain assets, including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark Aps), a wholly-owned subsidiary of Sanofi and over 250 patents and patent applications of Sanofi and certain of its subsidiaries and assumed certain liabilities for purposes of acquiring a portion of the CTRM business, which researches, develops, manufactures, markets and sells Carticel, MACI and Epicel (the CTRM Transaction). In consideration for the acquisition of the CTRM business, we paid a total purchase price of approximately $6.5 million, as follows: (a) $4 million was paid in cash on the closing date of the CTRM Transaction, and (b) a $2.5 million promissory note which was paid on July 30, 2014.

Concurrent with the closing of the CTRM Transaction, we and Sanofi entered into (i) certain IP assignment and license agreements to effect the transfer and license of the intellectual property related to the CTRM Business assigned and/or licensed to us, (ii) certain assignment and assumption of lease agreements for each of the real property leases being assigned to us, and (iii) transition services and transition supply agreements.

In consideration for the acquisition of the CTRM business, we paid a total purchase price of approximately $6.5 million, as follows: (a) $4.0 million was paid in cash on the closing date of the CTRM Transaction, and (b) a $2.5 million promissory note which we repaid on July 30, 2014. In accordance with generally accepted accounting principles in the United States of America (U.S. GAAP), we recorded the assets and liabilities of the CTRM business at fair value. The net assets of the CTRM business were valued at $10.0 million, which is in excess of the $6.5 million purchase price, which resulted in a $3.5 million bargain purchase gain. The primary driving factor for the bargain purchase gain was the structure of the CTRM Transaction. As part of the CTRM Transaction, Sanofi funded the Danish subsidiary with $5.0 million in cash in order to fund the restructuring of the Denmark operations and close the facility. Under U.S. GAAP, no restructuring actions were taken by Sanofi prior to our purchase of the CTRM business, and accordingly, there were no restructuring related accruals in the opening balance sheet. Additionally, there were no restrictions on the use of the cash in the Danish subsidiary. In 2014, we implemented our restructuring plans for the Danish subsidiary after the consummation of the CTRM Transaction and recorded restructuring charges in the US and Denmark of $3.0 million and all restructuring expenses were paid by September 30, 2015.

Manufacturing

We acquired two cell-manufacturing facilities as part of the acquisition of the CTRM business in Cambridge, Massachusetts and Copenhagen, Denmark. The Cambridge facility, which is approved by the U.S. Food and Drug Administration (FDA), is used for U.S. manufacturing and distribution of Carticel, Epicel manufacturing and also manufactured MACI for the SUMMIT study conducted for approval in Europe. The Copenhagen manufacturing facility, which was approved by the Danish Medicines Agency (DKMA), was responsible for MACI manufacturing and distribution in Europe. As part of the June 2014 restructuring, we discontinued MACI manufacturing at the Copenhagen manufacturing facility. Going forward, we expect that any clinical and commercial production of MACI will occur at our Cambridge facility.

We also operate a centralized cell manufacturing facility in Ann Arbor, Michigan. The facility supports the current ixCELL-DCM clinical trial being conducted in the United States and Canada and we believe we have sufficient capacity, with minor modifications, to supply our early commercialization requirements.

Product Portfolio

Our approved and marketed products were acquired through the CTRM Transaction and include three approved autologous cell therapy products, each of which are further described below: Carticel (autologous cultured chondrocytes), a first-generation product for autologous chondrocyte implantation (ACI) currently marketed in the U.S., MACI (matrix-applied characterized autologous cultured chondrocytes), a third-generation ACI product that was approved in Europe where we have temporarily suspended sales, and Epicel (cultured epidermal autografts), a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area. Our product candidate portfolio also includes ixmyelocel-T, a patient-specific multicellular therapy currently in development for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

Carticel

Carticel, a first-generation ACI product for the treatment and repair of cartilage defects in the knee, is the first and only FDA-approved autologous cartilage repair product. Carticel is indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea) caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure such as debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft. Carticel received a Biologics License Application (BLA) approval in 1997 and is currently marketed in the U.S. It is generally used on patients with larger lesions (greater than 3 cm2).

In the U.S., we focus our sales of Carticel on the sports-injury-targeted orthopedic physician target audience, which is very concentrated, with 60% of the current Carticel business originating from 25% of this audience, or approximately 110 physicians. We currently have a 21-person field force calling on this sports-injury targeted orthopedic physician audience.

Epicel

Epicel is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area (TBSA). Epicel is regulated by the Center for Biologics Evaluation and Research (CBER) under medical device authorities, and is the only FDA-approved autologous epidermal product available for large total surface area burns. Epicel was designed as a Humanitarian Use Device (HUD in 1998 and a Humanitarian Device Exemption (HDE) application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect or are manifested in fewer than 4,000 individuals annually in the United States. Currently, approximately less than 100 patients are treated with Epicel in the U.S. each year. For the three and nine months ended September 30, 2015, net revenues were $3.2 million and $11.2 million for Epicel, respectively.

Under the HDE approval of 2007, Epicel cannot not be sold for an amount that exceeds the cost of research and development, fabrication and distribution. However, pursuant to the Pediatric Medical Device Safety and Improvement Act of 2007 and the FDA Safety and Innovation Act of 2012 (FDASIA), a HUD can be sold for profit if certain conditions are met. Under current law as amended by FDASIA, an HDE holder can make a profit on its HUD after receiving HDE approval if the device is intended for the treatment or diagnosis of a disease or condition that occurs in pediatric patients or in a pediatric subpopulation, and such device is labeled for use in pediatric patients or in a pediatric subpopulation in which the disease or condition occurs; or is intended for the treatment or diagnosis of a disease or condition that does not occur in pediatric patients or that occurs in pediatric patients in such numbers that the development of the device for such patients is impossible, highly impracticable, or unsafe. If the FDA makes a determination that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit after receiving HDE approval as long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (ADN) for the device. The ADN is determined by FDA when it approves the original HDE application, or when the agency approves an HDE supplement for an HDE approved before the enactment of FDASIA, if the HDE holder seeks a determination for the HUD in an HDE supplement based upon the profit-making eligibility criteria, and FDA determines that the HUD meets the eligibility criteria.

We are currently investigating Epicel’s eligibility for an exemption from the profit prohibition and held a pre-submission meeting with the FDA to discuss the process and required data for submitting an HDE supplement to obtain an exemption from the profit prohibition. We plan to submit an HDE supplement to the FDA in the fourth quarter of 2015 to revise the labeled indications for use of Epicel to specifically include pediatric patients and to add pediatric labeling for Epicel. Epicel is currently being sold at a price that reflects the cost of research and development, fabrication and distribution.

We currently have a 4-person field force calling upon dedicated burn centers.

MACI

MACI is a third-generation ACI product for the treatment of focal chondral cartilage defects in the knee. MACI received marketing authorization in Europe in July 2013 by meeting the requirements of the Advanced Therapy and Medicinal Product (ATMP) guidelines. MACI had been commercially available in the European Union (EU) since 1998. As part of the June 2014 restructuring we temporarily suspended sales of MACI in August 2014, primarily due to low utilization and an unfavorable pricing environment. We believe that MACI has significant revenue potential in the U.S., if approved and reimbursed. We plan to submit a BLA to the FDA by the end of 2015 for MACI. The timing and strategy for a possible reintroduction in select EU countries have not yet been determined.

MACI was obtained by Sanofi by acquiring Verigen AG (Verigen) in 2005. As part of Sanofi’s acquisition of Verigen, Sanofi agreed to make cash payments to Verigen upon the achievement of developmental milestones relating to regulatory and commercialization of MACI in the United States. In connection with our acquisition of the CTRM business, we agreed that if we further developed MACI in the U.S., we would be obligated to pay these milestone payments. During the third quarter of 2014, at our request, Sanofi entered into a settlement agreement with the former shareholders of Verigen whereby these shareholders agreed to discharge all obligations related to these MACI milestone payments in exchange for a one-time cash payment of €2.5 million (approximately $3.2 million). We paid this amount in full in October 2014.

Ixmyelocel-T

Our preapproval stage portfolio also includes ixmyelocel-T, a unique patient-specific multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. Our proprietary cell manufacturing process significantly expands the mesenchymal stromal cells (MSCS) and M2-like anti-inflammatory macrophages in the patient’s bone marrow mononuclear cells while retaining many of the hematopoietic cells. These cell types are known to regulate the immune response and play a key role in tissue repair and regeneration by resolving pathologic inflammation, promoting angiogenesis, and remodeling ischemic tissue. The novelty and advantage of using ixmyelocel-T is the expansion of a unique combination of cell populations, including MSCS and M2-like macrophages, which secrete a distinct combination of angiogenic and regenerative factors, and possess the ability to remain anti-inflammatory in the face of inflammatory challenge.

Our lead clinical development program for ixmyelocel-T is focused on severe, chronic ischemic cardiovascular diseases. We are currently conducting the Phase 2b ixCELL-DCM study, which is a randomized, double-blind, placebo-controlled clinical trial for patients with advanced heart failure due to ischemic DCM. Ixmyelocel-T has been granted a U.S. Orphan Drug designation by the FDA for the treatment of DCM. We also have an ongoing ixmyelocel-T clinical program for the treatment of craniofacial reconstruction and have conducted clinical studies for the treatment of critical limb ischemia.

The ongoing Phase 2b ixCELL-DCM clinical study has treated 114 patients at 28 sites in the U.S. and Canada. Patients will be followed for 12 months for the primary efficacy endpoint of major adverse cardiovascular events, defined as all-cause deaths, all-cause hospitalizations, and unplanned outpatient or emergency department visits for IV treatment of acute worsening heart failure. Secondary endpoints include clinical, functional, structural, symptomatic, quality of life, and biomarker measures at 3, 6 and 9 months. Patients will be followed for an additional 12 months for safety. We completed enrollment of the ixCELL-DCM study in January 2015, and expect to have top-line efficacy results around the end of the first quarter of 2016.

Results of Operations

Net Loss

Our net loss for the three and nine months ended September 30, 2015 totaled $4.4 million or $0.26 per share and $11.4 million or $0.69 per share, respectively.

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Total revenues $11,309 $9,658 $35,748 $14,090
Cost of product sales 6,772 5,532 19,241 10,541
Gross profit 4,537 4,126 16,507 3,549
Total operating expenses 9,414 12,148 28,221 24,737
Loss from operations (4,877) (8,022) (11,714) (21,188)
Other income (expense) 461 1,105 284 3,638
Net loss $(4,416) $(6,917) $(11,430) $(17,550)

Net Revenues

Revenue by product (in thousands) Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Carticel $7,736 $7,459 $23,917 $10,904
Epicel 3,246 1,769 11,159 2,697
Bone Marrow 327 244 672 303
MACI — 186 — 186
$11,309 $9,658 $35,748 $14,090

Net revenues increased for the three months ended September 30, 2015 compared to the same period the previous year due primarily to increased Epicel implants and increases in the prices we charge for our products that took effect in the current period.

Period comparisons for net revenues by product for the nine months ended are not yet meaningful due to the timing of the acquisition of the CTRM Business in May 2014.

Seasonality. Carticel revenue is subject to seasonal fluctuations with stronger sales occurring in the fourth quarter and second quarter due to a number of factors including insurance copay limits and the time of year patients prefer to start rehabilitation. During 2014, the percentage of annual sales by quarter was as follows: 21.6% in the first quarter, 23.7% in the second quarter, 21.8% in the third quarter, and 32.9% in the fourth quarter. Epicel revenue is also subject to seasonal fluctuations mostly associated with the use of heating elements during the colder months, with stronger sales occurring in the winter months of the first and fourth quarters, and weaker sales occurring in the hot summer months of the third quarter. However, in any single year, this trend can be absent due to the extreme variability inherent with Epicel’s low patient volume of fewer than 100 patients per year. Over the last four years, the percentage of annual sales by quarter was as follows: first quarter, 28%; second quarter, 24%; third quarter, 20%; and fourth quarter, 28%. The variability between the same quarters in consecutive years has been as high as 10% of the annual volume. While the number of patients treated per year remains low, we expect these large swings in revenue in some quarters to continue. These seasonal trends have caused and will likely continue to cause, fluctuations in our quarterly results, including fluctuations in sequential revenue growth rates.

Gross Profit and Gross Profit Ratio

Period comparison for gross profit for the nine months ended September 30, 2015 and 2014 is not yet meaningful due to the timing of the acquisition of the CTRM Business.

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015
Gross profit $4,537 $4,126 $16,507
Gross profit % 40.1% 42.7% 46.2%

18

Gross profit ratio decreased for the three months ended September 30, 2015 compared to the same period the previous year due to an increase in cost of goods sold due to an increase in software and equipment purchases and facility modifications of $0.6 million as a result of the integration of the CTRM business and above normal inventory write-offs of $0.4 million which we do not expect to reoccur.

Research and Development Costs

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Research and development costs $3,740 $7,835 $11,486 $15,470

Research and development expenses for the three months ended September 30, 2015 were $3.7 million versus $7.8 million for the same period a year ago and were $11.5 million versus $15.5 million for the nine months ended September 30, 2015 versus the same period a year ago. The decrease in research and development expenses is a result of the ixCELL-DCM study, which completed enrollment in January 2015 and incurred minimal expenses in 2015 versus 2014 in addition to the canceled Critical Limb Ischemia study. In addition, during the three months ended September 30, 2014, at our request, Sanofi entered into a settlement agreement with the former shareholders of Verigen whereby these shareholders agreed to discharge all obligations related to these MACI milestone payments in exchange for a one-time cash payment of €2.5 million (approximately $3.2 million) due within two months from the date when all parties sign the settlement agreement. We are a third-party beneficiary of the settlement agreement and, as agreed in connection with the acquisition of the CTRM Business, we were responsible for reimbursing Sanofi for this €2.5 million payment. The decrease was partially offset by additional research, development and regulatory costs incurred for Carticel and Epicel.

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Dilated Cardiomyopathy $1,930 $3,634 $7,229 $10,232
Critical Limb Ischemia — 261 — 805
MACI - Verigen 903 3,158 1,509 3,158
Carticel 409 212 1,409 318
Epicel 498 105 1,339 180
MACI — 465 — 777
Total research and development expenses $3,740 $7,835 $11,486 $15,470

Selling, General and Administrative Costs

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Selling, general and administrative costs $5,674 $4,313 $16,735 $9,267

Selling, general and administrative expenses for the three months ended September 30, 2015 were $5.7 million compared to $4.3 million for the same period in the previous year. The increase in selling, general and administrative expenses is primarily due to an increase of $1.3 million in sales and marketing expenses associated with Carticel and Epicel as well as strategic planning activities for MACI, and approximately $0.6 million of increased personnel costs to manage the expanded business. These increases were partially offset by a decrease in professional service fees which were incurred in 2014 related to the acquisition of the CTRM business.

Selling, general and administrative expenses for the nine months ended September 30, 2015 were $16.7 million compared to $9.3 million for the same period the previous year. The increase in selling, general and administrative expenses is due to approximately $6.4 million in sales and marketing expenses from the CTRM business and approximately $1.8 million in increased information technology, legal, consulting and personnel costs related to integrating and managing the CTRM business in the U.S.

Other Income (Expense)

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Decrease (increase) in fair value of warrants $461 $949 $256 $(155)
Bargain purchase gain — — — 3,634
Foreign currency translation gain (loss) (5) 154 5 154
Net interest income 5 2 23 5
Total other income (expense) $461 $1,105 $284 $3,638

The change in the fair value of warrants for the three and nine months ended September 30, 2015 was primarily due to the decrease in our stock price, the reduction in the time to maturity and the expiration of the January 2010 Class A warrants which were unexercised. Fluctuations in the fair value of the warrants in future periods could result in significant non-cash adjustments to the condensed consolidated financial statements, however, any income or expense recorded will not impact our cash, operating expenses or cash flow.

The bargain purchase gain of $3.6 million for the nine months ended September 30, 2014 represents the gain associated with the acquisition of the CTRM Business on May 30, 2014.

Stock Compensation

Non-cash stock-based compensation expense included in cost of goods sold, research and development expenses and selling, general and administrative expenses is summarized in the following table:

(In thousands)

Three Months Ended September 30, 2015 2014 Nine Months Ended September 30, 2015 2014
Cost of goods sold $59 $— $245 $—
Research and development 109 64 467 129
Selling, general and administrative 406 138 1,476 524
Total non-cash stock-based compensation expense $574 $202 $2,188 $653

The increase in stock-based compensation expense is due primarily to an increase in options granted in the three and nine months ended September 30, 2015 compared to the same period in 2014 as a result of an increase in the number of employees as a result of the acquisition of the CTRM business.

Liquidity and Capital Resources

We are currently focused on utilizing our technology to identify, develop and commercialize innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Until such time as we satisfy, if at all, applicable regulatory approval requirements for ixmyelocel-T and MACI, we expect the sales of Carticel and Epicel therapies to constitute nearly all of our product sales revenues. Additionally, we are focusing significant resources to successfully integrate and grow our CTRM business.

While we believe we have adequate cash to achieve a positive cash flow, we do not expect to generate positive cash flows from our consolidated operations for at least a year and then only if we achieve a combination of product sales growth, improved product margins, and lower selling, general and administrative expenses and research and development expenses.

We have raised significant funds in order to complete our product development programs, and complete clinical trials needed to market and commercialize our products. To date, we have financed our operations primarily through public and private sales of our equity securities. The current cash on hand will be sufficient to sustain operations until we become cash flow positive, however, if actual results differ from our projections, we may need to access additional capital. We have access to certain amounts of financing through an agreement with Lincoln Park Capital Fund, LLC (Lincoln Park). We may direct Lincoln Park to purchase up to $15.0 million worth of shares of our common stock over a 30-month period generally in amounts up to 50,000 shares of our common stock on certain business days under a Purchase Agreement. However, there are certain factors, such as volume of trading in our common stock and our stock price, which limit the amount that can be raised in a short period of time. The extent to which we rely on the Lincoln Park Equity Line as a source of funding will depend on a number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. The remaining capacity under this agreement is $11.3 million.

At September 30, 2015 there was approximately $7.8 million of net capacity remaining on the At-the-Market Sales Agreement with MLV & Co. LLC (formerly McNicoll, Lewis & Vlak), which allowed us to sell our common stock from time to time under a registration statement on Form S-3 filed in June 2011, pursuant to which we registered $100 million of our securities for public sale. The Form S-3 registration statement filed in June 2011 expired in July 2014. If we choose to access the remaining capacity, we will file an updated Form S-3 registration statement.

Our cash totaled $18.7 million at September 30, 2015. During the nine months ended September 30, 2015, the primary uses of cash included $9.3 million for our operations and working capital requirements. This use of funds was fueled largely by our operating loss reduced by stock compensation expense of $2.2 million as a result of an increase in personnel, depreciation and amortization expense of $1.2 million as a result of required capital expenditures in conjunction with the purchase of the CTRM business and inventory provision of $0.6 million. The reductions were offset by an increase in accrued expenses of $1.1 million due primarily to an increase in employee related expenses as a result of the additional employees, an increase in accounts payable of $0.9 million primarily related to timing of payments and expenses incurred since the CTRM business has been fully integrated, and a decrease in fair value of warrants of $0.3 million.

The change in cash used for investing activities is the result of material property plant and equipment purchases as a result of integration of the CTRM business through September 30, 2015 offset by the acquisition of the CTRM business in 2014.

The change in cash provided from financing activities is the result of the September 2014 equity raise as well as Lincoln Park and ATM activity in 2014, all of which did not occur as of September 30, 2015.

As of September 30, 2015 we had $13.5 million of cash deposited into an Insured Cash Sweep (ICS) program which is administered by Bank of New York Mellon. This program maximizes our Federal Deposit Insurance Company (FDIC) coverage by dividing our ICS funds into amounts under the standard FDIC maximum and places these amounts with other ICS Network member banks (each an FDIC-insured institute). These funds are placed in savings accounts at the member banks earning interest while still maintaining insurance coverage.

While we believe that our current cash will be sufficient to sustain operations until the business becomes cash flow positive, actual cash requirements may differ from projections and will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patents, competing technological and market developments, costs of possible acquisition or development of complementary business activities, and the cost of product launch and commercialization of newly approved products. If MACI receives the required FDA approvals, we may need to raise additional capital in anticipation of introduction of MACI in the U.S. markets.

Off-Balance Sheet Arrangements

At September 30, 2015, we were not party to any off-balance sheet arrangements.

Significant Accounting Policies

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of these condensed consolidated financial statements requires the application of appropriate technical accounting rules and guidance, as well as the use of estimates. The application of these policies necessarily involves judgments regarding future events. These estimates and judgments, in and of themselves, could materially impact the condensed consolidated financial statements and disclosures based on varying assumptions. The accounting policies discussed in our Form 10-K for the fiscal year ended December 31, 2014 are considered by management to be the most important to an understanding of the consolidated financial statements because of their significance to the portrayal of our financial condition and results of operations. There have been no material changes to that information disclosed in our Form 10-K for the fiscal year ended December 31, 2014.

Forward-Looking Statements

This report, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “estimates,” “plans,” “projects,” “trends,” “opportunity,” “comfortable,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “achieve,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. The factors described in our Annual Report on Form 10-K filed with the SEC on March 25, 2015, among others, could have a material adverse effect upon our business, results of operations and financial conditions.

Because the factors referred to in the preceding paragraph could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements we make, you should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These forward-looking statements include statements regarding:

  • potential strategic collaborations with others;
  • future capital needs and financing sources;
  • adequacy of existing capital to support operations for a specified time;
  • product development and marketing plan;
  • regulatory filing plans;
  • features and successes of our cellular therapies;
  • manufacturing and facility capabilities;
  • clinical trial plans and anticipated results, including publication thereof:
  • anticipation of future losses;
  • replacement of manufacturing sources;
  • integration of the CTRM business and assets;
  • commercialization plans; or
  • revenue expectations and operating results.

Market risk

As filed, 599 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of September 30, 2015, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio.

We operate in the United States of America and have closed operations in Denmark. We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities. Our vendors in countries outside the United States are typically paid in Euro and/or Danish Krone. We do not enter into hedging transactions and do not purchase derivative instruments.

Controls and procedures

As filed, 1,432 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its “Certifying Officers”), as appropriate, to allow timely decisions regarding required disclosure.

The Company carried out an evaluation, under the supervision and with the participation of its management, including the Certifying Officers of the effectiveness of the Company’s disclosure controls and procedures as defined in Rules l3a-15(e) and l5d-15(e) under the Exchange Act. Based on the evaluation as of September 30, 2015, our Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There have been no changes in internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 348 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Information regarding our risk factors is set forth in Part 1, Item 1A, “Risk Factors,” on our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 25, 2015. There have been no material changes in our risk factors from those disclosed in Part 1, Item 1A, “Risk Factors” on our Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-07-01 to 2015-09-30$11.3mus-gaap:SalesRevenueNet
Revenue9 months2015-01-01 to 2015-09-30$35.7mus-gaap:SalesRevenueNet
Cost of revenue3 months2015-07-01 to 2015-09-30$6.8mus-gaap:CostOfGoodsSold
Cost of revenue9 months2015-01-01 to 2015-09-30$19.2mus-gaap:CostOfGoodsSold
Gross profit3 months2015-07-01 to 2015-09-30$4.5mus-gaap:GrossProfit
Gross profit9 months2015-01-01 to 2015-09-30$16.5mus-gaap:GrossProfit
Research and development3 months2015-07-01 to 2015-09-30$3.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2015-01-01 to 2015-09-30$11.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2015-07-01 to 2015-09-30$5.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2015-01-01 to 2015-09-30$16.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2015-07-01 to 2015-09-30−$4.9mus-gaap:OperatingIncomeLoss
Operating income9 months2015-01-01 to 2015-09-30−$11.7mus-gaap:OperatingIncomeLoss
Interest expense3 months2015-07-01 to 2015-09-30$2.0kus-gaap:InterestExpense
Interest expense9 months2015-01-01 to 2015-09-30$6.0kus-gaap:InterestExpense
Net income3 months2015-07-01 to 2015-09-30−$4.4mus-gaap:NetIncomeLoss
Net income9 months2015-01-01 to 2015-09-30−$11.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2015-07-01 to 2015-09-30−$0.26us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2015-01-01 to 2015-09-30−$0.69us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2015-01-01 to 2015-09-30−$9.3mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure9 months2015-01-01 to 2015-09-30$2.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-09-30$18.7mus-gaap:Cash
Current assetsAt period end2015-09-30$28.5mus-gaap:AssetsCurrent
Total assetsAt period end2015-09-30$35.8mus-gaap:Assets
Current liabilitiesAt period end2015-09-30$9.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-09-30$9.4mus-gaap:Liabilities
Long-term debtAt period end2015-09-30$81.0kus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2015-09-30$26.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-15-008745. Last ingested by Listed: Nov 14, 2026, 12:33 ET. Listed shows no prices and gives no investment advice.